Haiming Chen

First Affiliated Hospital of Nanchang University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Xu Shu

First Affiliated Hospital of Jiangxi Medical College

Yunfeng Huang

Biogen (United States)

Weiguang Gu

Southern Medical University

Yiyu Lu

Guangdong Medical College

Foqiang Liao

First Affiliated Hospital of Nanchang University

Minhong He

Southern Medical University

Xinfu Liu

Qingdao University of Technology

Lianglong Chen

Union Hospital

Yichao Huang

China University of Petroleum, East China

Xin-Fu Liu

The Central Hospital of Shaoyang

Cooperative Institutions

Southern Medical University

First Affiliated Hospital of Nanchang University

Nanchang University

South China University of Technology

Nanfang Hospital

Qingdao University of Technology

The Central Hospital of Shaoyang

University of South China

First Affiliated Hospital of Jiangxi Medical College

Union Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

ASO Author Reflections: Self-expanding Metal Stents for Right-Sided Colonic Cancer Obstruction

Annals of Surgical Oncology (2024)

Yunfeng Huang Foqiang Liao Haiming Chen Xu Shu

Surgical oncology

10.1245/s10434-024-15054-w

Cite

Citations (2)

Pretreatment Serum Ferritin as a Prognostic Indicator in Advanced Cancer Patients Treated With Apatinib: A Retrospective Cohort Study

Research Square (Research Square) (2020)

Haiming Chen Yichao Huang Xin-Fu Liu Yiyu Lu Weiguang Gu

Abstract Background: The present study has evaluated the prognostic value of pretherapy serum ferritin (SF) levels in advanced cancer patients receiving apatinib therapy after multiline treatment for drug resistance. Methods: This retrospective cohort reviewed the clinicopathological characteristics and pretreatment levels of SF of 124 patients with advanced cancer treated with apatinib. The Kaplan-Meier method was used to calculate the overall survival rate (OS) and progression-free survival (PFS), and the log-rank test was used to assess the statistical significance. Univariate and multivariate analyses of Cox proportional hazard regression were used to assess the prognostic impact of advanced cancer. Results: Participants in this study were previously treated with at least two treatment regimens. 52.4% of the patients had the Eastern Cooperative Oncology Group Performance Status (ECOG-PS)≥2. Median PFS was 8.57 weeks, and the median overall survival was 9.43 weeks. The OS and PFS of patients with elevated SF were significantly shorter than those with low SF (p <0.001 and p <0.001, respectively). Conclusions: SF can be used as an important prognostic indicator for advanced cancer patients with the treatment of apatinib after multiline treatment for drug resistance.

Apatinib

Progression-free survival

10.21203/rs.3.rs-87127/v1

Cite

Citations (0)

Efficacy and Safety Analysis of Emergency Endoscopic Self-Expanding Metal Stent Placement Without Fluoroscopic Assistance for Right-Sided Colonic Cancer Obstruction

Annals of Surgical Oncology (2024)

Yunfeng Huang Foqiang Liao Zhenyi Zhan Lianglong Chen Haiming Chen

Surgical oncology

10.1245/s10434-024-14909-6

Cite

Citations (2)

Apatinib successfully administered in malignant tumour patients with severe hypotension: a case series, literature review, and considerations for treatment

Journal of International Medical Research (2023)

Haiming Chen Xinfu Liu Minhong He Weiguang Gu Yiyu Lu

The most notable side-effect of apatinib, a novel antiangiogenic agent for the treatment of cancer, is hypertension, but there are few published studies regarding the use of apatinib to treat patients with cancer and severe hypotension. Here, the cases of three patients with tumours and severe hypotension are described: case 1, a 73-year-old male patient with lung squamous cell carcinoma who initially received radiotherapy and chemotherapy, and developed pneumonia and severe hypotension after 6 months; case 2, a 56-year-old male patient with nasopharyngeal carcinoma who was treated with chemotherapy and presented with fever and persistent hypotension; and case 3, a 77-year-old male patient with oesophageal cancer who was admitted with deglutition difficulty and severe hypotension. Apatinib was added to the treatment regimen of all three patients for antitumor therapy. Pneumonia, tumour progression, and severe hypotension improved noticeably in all patients within 1 month after receiving apatinib. Apatinib was associated with a positive effect on blood pressure stability, in synergy with other means of therapy, and the patients achieved satisfactory short-term clinical results. The role of apatinib in treating patients with cancer and hypotension merits further investigation.

Apatinib

10.1177/03000605231177186

Cite

Citations (0)